This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Spinraza
  • /
  • Study of Nusinersen (BIIB058) in Participants With...
Clinical trial

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

Read time: 3 mins
Last updated:26th Feb 2020
Identifier: NCT04089566

The primary objective of the study is to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA).

The secondary objectives of the study are to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA; to examine the effect of nusinersen administered at higher doses compared to the currently approved dose in participants with SMA; and to examine the pharmacokinetic(s) (PK) of nusinersen [cerebrospinal fluid (CSF) and plasma] after intrathecal administration of nusinersen given at higher doses to participants with SMA.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 125 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Estimated Study Start Date: February 26, 2020
Estimated Primary Completion Date: June 13, 2022
Estimated Study Completion Date: December 18, 2022

Arms:
- Experimental:
28/28 Milligram (mg) Safety Group
- Active Comparator: 12/12 mg Randomized Control Group
- Experimental: 50/28 mg Randomized Treatment Group
- Experimental: 12/50/28 mg Titration Group

Category Value
Date last updated at source 2019-09-13
Study type(s) Interventional
Expected enrolment 125
Study start date 2020-02-26
Estimated primary completion date 2022-06-13

View full details